Comment on: "Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. Gastric cancer, 2021 Aug 11" by Iwatsuki et al
Gastric Cancer
.
2021 Nov;24(6):1376-1377.
doi: 10.1007/s10120-021-01247-9.
Epub 2021 Sep 13.
Authors
Yongfeng Ding
1
,
Junjie Jiang
2
,
Nong Xu
3
Affiliations
1
Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
2
Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
3
Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
[email protected]
.
PMID:
34515901
DOI:
10.1007/s10120-021-01247-9
No abstract available
Publication types
Letter
Comment
MeSH terms
Adenocarcinoma* / drug therapy
Esophagogastric Junction
Humans
Neoadjuvant Therapy
Oxaliplatin
Stomach Neoplasms* / drug therapy
Substances
Oxaliplatin